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This Talk will cover… 
Drug Screening (in vitro, bioinformatics) 
Clinical trial 





HCV in Kazakhstan (EHRN)        
20-50% in high risk groups 
4 
Mild Moderate Severe 
15%-30% 70%-85% 
Acute HCV Infection 
Recovery Chronic HCV Infection 
Cirrhosis  















































Cell Culture models 
Enzyme assays 
Bioinformatics 
Drug Screening for HCV 





HCV NS3   
Helicase  
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Drug Screening for HCV 
Huh8 cells 
HCV Replicon 













Drug Screening for HCV 
Huh7 cells 
HCV virion 
Infect cells with HCV 
Incubate cells with drug 
Quantify HCV RNA 
13 








Drug Screening for HCV 
HCV NS3  
Helicase  
Purify viral helicase 
Measure activity  





Drug-Target interactions  




































































    Levofloxacin       Lomefloxacin        Ciprofloxacin        Enrofloxacin 
Drug-Target interactions  
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Summary 
HCV NS3 helicase inhibitors: 
 
  HCV replicon 
      HCV virion synthesis 
   HCV helicase 
  Computer modeling 











CANCER & VIRUS LAB   
 
AFSHAN 
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